TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3047581

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.15 mg per kilogram of body weight every six hours for four days)
Number of subjects: 200
Study: 2025471

Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg (for diazepam sedation)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: flumazenil 0.1-2 mg (for midazolam sedation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: flumazenil 0.1-2 mg and placebo
Number of subjects: 120
Study: 795260

Group type: EXPERIMENTAL
Intervention: Fructose (F)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Xylitol (X)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sucrose (S)
Number of subjects: 125
Study: 31791415

Group type: EXPERIMENTAL
Intervention: Intervention package (condom promotion, HIV and syphilis testing, reimbursement for syphilis treatment costs, and free anti-retroviral therapy)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 1024
Study: 28720121

Group type: EXPERIMENTAL
Intervention: Daily SMS reminders of antihypertensive medication intake provided by pharmacists in addition to standard pharmaceutical care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard pharmaceutical care
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Daily SMS reminders
Number of subjects: 300
Study: 26096637

Group type: EXPERIMENTAL
Intervention: Perampanel (4, 8, and 12 mg)
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1478
Study: 23442091

Group type: EXPERIMENTAL
Intervention: Episodic future thinking task in older adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Episodic future thinking task in young adults
Number of subjects: 0
Study: 21422479

Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose doxycycline (SDD)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 19221011

Group type: EXPERIMENTAL
Intervention: 50 g sucrose in water (500 ml)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 80 mg sucralose in 500 ml normal saline (0.4 mM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 800 mg sucralose in 500 ml normal saline (4 mM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: 500 ml normal saline
Number of subjects: 7
Study: 18218205

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 23
Study: 15166004

Group type: EXPERIMENTAL
Intervention: C12 (lauric acid)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: C10 (decanolic acid)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study: 11286849

Group type: EXPERIMENTAL
Intervention: 68 Gy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Accelerator A (used for treatment)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Accelerator B (used for treatment)
Number of subjects: 225
Study: 9885079

Group type: EXPERIMENTAL
Intervention: Complex maze
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simple maze
Number of subjects: 20
Study: 7993937

Group type: EXPERIMENTAL
Intervention: GM-CSF primed-PBPC
Number of subjects: 23
Study: 2729180

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide (2 mg/kg X 4)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus high-dose methylprednisolone (250 mg X 2)
Number of subjects: 34
Study: 29649914

Group type: EXPERIMENTAL
Intervention: Positive affect skills intervention
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 159
Study: 30974969

Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE) plus allergen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE) plus allergen
Number of subjects: 14

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Particle-depleted diesel exhaust (PDDE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Diesel exhaust (DE)
Number of subjects: 14
Study: 26122046

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation (low tidal volume, positive end-expiratory pressure, recruitment maneuvers)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Non-protective ventilation (high tidal volume, zero end-expiratory pressure)
Number of subjects: 95
Study: 23537420

Group type: EXPERIMENTAL
Intervention: Nocturnal continuous glucose monitoring (CGM)
Number of subjects: 72
Study: 21528597

Group type: EXPERIMENTAL
Intervention: Acupuncture and moxibustion group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 100
Study: 19041352

Group type: EXPERIMENTAL
Intervention: Tdap3v
Number of subjects: 2284

Group type: COMPARATOR
Intervention: Tdap5v
Number of subjects: 2284
Study: 16750448

Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 110

Group type: COMPARATOR
Intervention: latanoprost 0.005%/timolol 0.5%
Number of subjects: 110
Study: 15336988

Group type: EXPERIMENTAL
Intervention: Bicaval orthotopic heart transplantation with DeVega tricuspid valve annuloplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bicaval orthotopic heart transplantation
Number of subjects: 60
Study: 11339688

Group type: EXPERIMENTAL
Intervention: Salt-sensitive individuals (n = 16)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Salt-resistant individuals (n = 27)
Number of subjects: 43
Study: 9470834

Group type: EXPERIMENTAL
Intervention: CVI 5‐FU at a dose of 750 mg/m2/day, 7 d every 21 d (n = 77)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Bolus 5‐FU 500 mg/m2/d x 5 d every 28 d (n = 78)
Number of subjects: 155
Study: 7943788

Group type: EXPERIMENTAL
Intervention: Succinylcholine 100 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine 175 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine 250 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine 375 micrograms/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 40
Study: 3370065

Group type: EXPERIMENTAL
Intervention: 2.5 mg torasemide once daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 5 mg torasemide once daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Higher dosages of torasemide for non-responders
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Torasemide treatment
Number of subjects: 87
Study: 30328307

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using grafts and collagen membranes
Number of subjects: 25
Study: 26847813

Group type: EXPERIMENTAL
Intervention: Temozolomide plus Bevacizumab (TMZ + BEV)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 102
Study: 23795708

Group type: EXPERIMENTAL
Intervention: More numerate adults making decisions among a small number of alternatives (2 to 16 plans)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Less numerate adults making decisions among a small number of alternatives (2 to 16 plans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Numeracy as a moderator
Number of subjects: 0
Study: 21093231

Group type: EXPERIMENTAL
Intervention: Olive oil meal (22% SFA, 38% MUFA, 4% PUFA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Butter meal (35% SFA, 22% MUFA, 4% PUFA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Walnuts meal (20% SFA, 24% MUFA, 16% PUFA, 4% α-linolenic acid)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (Olive oil meal)
Number of subjects: 21
Study: 19768454

Group type: COMPARATOR
Intervention: Bupivicaine 0.5% (20 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5% (20 ml) with 10 mg morphine
Number of subjects: 60
Study: 18333861

Group type: EXPERIMENTAL
Intervention: Maraviroc (3-1200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16003291

Group type: EXPERIMENTAL
Intervention: Verapamil (240 mg daily for 6 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12
Study: 12479993

Group type: EXPERIMENTAL
Intervention: Therapist-administered group training (TG)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Self-help format (SH)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Waiting-list control group (WC)
Number of subjects: 77
Study: 10065784

Group type: EXPERIMENTAL
Intervention: IVF (group 1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard infertility treatment algorithm (group 2)
Number of subjects: 96
Study: 7752008

Group type: EXPERIMENTAL
Intervention: Preterm infant formula with higher concentrations of zinc, copper, calcium, magnesium, and potassium until 2 months past expected term
Number of subjects: 33

Group type: COMPARATOR
Intervention: Term infant formula
Number of subjects: 33
Study: 2257872

Group type: EXPERIMENTAL
Intervention: Rythmodan (conventionally formulated disopyramide) 150 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rythmodan 250 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rythmodan Retard (controlled‐release disopyramide) 250 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 496440

Group type: EXPERIMENTAL
Intervention: Ectocervical scraping and endocervical curettage
Number of subjects: 558

Group type: COMPARATOR
Intervention: Cone biopsy
Number of subjects: 558

Group type: COMPARATOR
Intervention: Primary hysterectomy
Number of subjects: 558
Study: 30962231

Group type: EXPERIMENTAL
Intervention: Goal-directed financial incentives for weight loss (up to $750 over 6 months for participating in an intensive weight management programme, self-monitoring weight and diet, and meeting physical activity guidelines)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Outcome-based financial incentives for weight loss (up to $750 over 6 months for achieving a ≥1.5% to ≥5% reduction in baseline weight)
Number of subjects: 795

Group type: COMPARATOR
Intervention: Provision of health behaviour change resources alone (1-year commercial weight loss programme membership, self-monitoring tools, health education, and monthly check-ins)
Number of subjects: 795
Study: 27100913

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation (IV bolus of 1 mcg/kg over 10 min followed by maintenance infusion of 0.5 mcg/kg/h)
Number of subjects: 76

Group type: COMPARATOR
Intervention: General Anesthesia (GA) with endotracheal intubation and balanced anesthesia
Number of subjects: 76
Study: 25773594

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 25439713

Group type: EXPERIMENTAL
Intervention: Schroth exercises combined with standard care for 6 months
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard care (observation or bracing)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Schroth exercises
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 258
Study: 22765352

Group type: EXPERIMENTAL
Intervention: Action observation treatment (observing video clips showing daily age-appropriate actions and imitating them)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (observing video clips with no motor content and executing the same actions as cases)
Number of subjects: 15
Study: 18812416

Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 29
Study: 19015065

Group type: EXPERIMENTAL
Intervention: Various therapeutic approaches including surgery, radiotherapy, and chemotherapy
Number of subjects: 0
Study: 15644821

Group type: EXPERIMENTAL
Intervention: 0.37 mg/kg/week
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.24 mg/kg/week
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.24‐‐>0.37 mg/kg/week
Number of subjects: 50
Study: 12891162

Group type: EXPERIMENTAL
Intervention: Web-based compliance monitoring device plus usual care
Number of subjects: 18

Group type: COMPARATOR
Intervention: Usual care only (Control)
Number of subjects: 18
Study: 10481520

Group type: EXPERIMENTAL
Intervention: Metacholine provocation in asthmatics
Number of subjects: 27

Group type: COMPARATOR
Intervention: Asymptomatic period in asthmatics
Number of subjects: 27
Study: 8570130

Group type: EXPERIMENTAL
Intervention: RT plus MLT (20 mg/daily orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: RT alone (60 Gy)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: RT plus MLT
Number of subjects: 30
Study: 1279821

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms per hour continuous intravenous infusion for three days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 4022350

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg) with prednisone
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 27
Study: 31618129

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (BC)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 403
Study: 29688582

Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (5-200 mg single-dose; 10-100 mg multiple-dose over 10 days)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (single-dose)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral esaxerenone (multiple-dose)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 27003763

Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24212326

Group type: EXPERIMENTAL
Intervention: Computer-tailored advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free fruit initiative
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Free healthy breakfast
Number of subjects: 0
Study: 24817035

Group type: EXPERIMENTAL
Intervention: JNJ 39758979 (600 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22448783

Group type: EXPERIMENTAL
Intervention: Lu AA21004 (75 mg single dosing, 60 mg multiple dosing)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Lu AA34443 (major metabolite)
Number of subjects: 97
Study: 19485963

Group type: EXPERIMENTAL
Intervention: Continuous feedback of outcome to patients and clinicians
Number of subjects: 294
Study: 17689896

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 15059637

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO) - 1000 mg vitamin C and 400 IU RRR-alpha-tocopheryl acetate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 21
Study: 11584934

Group type: EXPERIMENTAL
Intervention: Combination regimen (pentamidine 2 mg/kg IM on alternate days + allopurinol 15 mg/kg in three divided doses for 30 days)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Single regimen (pentamidine 4 mg/kg IM on alternate days for 15 injections in 30 days)
Number of subjects: 158
Study: 9617976

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8543488

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 173

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 173
Study: 1782768

Group type: EXPERIMENTAL
Intervention: Eugenol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limonene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-quenching material from a perfume/flavour company
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similar mixture prepared in laboratory
Number of subjects: 0
Study: 6813444

Group type: EXPERIMENTAL
Intervention: Valproic acid treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: D,L-carnitine (50 mg/kg/day) for four weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 25
Study: 31144648

Group type: EXPERIMENTAL
Intervention: TTI-based algorithm for detecting chest compressions
Number of subjects: 691
Study: 30585986

Group type: EXPERIMENTAL
Intervention: Bediol (13.4‐mg THC, 17.8‐mg CBD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cannabis varieties containing THC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29016701

Group type: EXPERIMENTAL
Intervention: Complex community-based intervention delivered through a face-to-face session followed by a series of text messages.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 69
Study: 25847054

Group type: EXPERIMENTAL
Intervention: ToM treatment
Number of subjects: 97

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 97
Study: 24599650

Group type: EXPERIMENTAL
Intervention: BMAC combined with PRP injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: No injection (control group)
Number of subjects: 20
Study: 22379071

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin/oral ciprofloxacin (arm B)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Inhaled colistin/oral ciprofloxacin (arm A)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 223
Study: 19118809

Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21180141

Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg/d (Q group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 18
Study: 15502602

Group type: EXPERIMENTAL
Intervention: d-threo-methylphenidate hydrochloride (d-MPH) at doses of 2.5, 5, or 10 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: d,l-threo-methylphenidate hydrochloride (dl-MPH) at doses of 5, 10, or 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 11335694

Group type: EXPERIMENTAL
Intervention: Nonpainful brushing on the nonparetic leg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nonpainful brushing on the paretic leg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Painful heat on both legs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pain localization on the nonparetic foot
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tactile stimulation of the nonparetic leg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pain activation for the nonparetic leg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tactile-evoked ipsilateral S1 activation
Number of subjects: 4
Study: 9523054

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic oral magnesium supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate infusions
Number of subjects: 0
Study: 8281875

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1865975

Group type: EXPERIMENTAL
Intervention: MSD vaccine
Number of subjects: 634

Group type: EXPERIMENTAL
Intervention: Pasteur vaccine
Number of subjects: 634

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 634
Study: 7469623

Group type: EXPERIMENTAL
Intervention: Aspirin (single dose ranging from 325 to 2,925 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Acetaminophen (single dose ranging from 975 to 1,950 mg)
Number of subjects: 19
Study: 31496051

Group type: EXPERIMENTAL
Intervention: ART (tenofovir-lamivudine-efavirenz)
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: ART for ≥12 months
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Testing during pregnancy, at delivery, and in postpartum
Number of subjects: 1623

Group type: EXPERIMENTAL
Intervention: Factors associated with viral suppression
Number of subjects: 1623
Study: 28187983

Group type: EXPERIMENTAL
Intervention: Intensified therapy
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 160
Study: 26033054

Group type: EXPERIMENTAL
Intervention: C‐stem AMT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Exeter
Number of subjects: 70
Study: 23553888

Group type: EXPERIMENTAL
Intervention: Primary PCI for STEMI (no specific dosage or duration mentioned)
Number of subjects: 870
Study: 19925199

Group type: EXPERIMENTAL
Intervention: Induced positive affect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cue-induced proactive preparation and maintenance processes
Number of subjects: 0
Study: 19438495

Group type: EXPERIMENTAL
Intervention: Microwave Endometrial Ablation
Number of subjects: 320

Group type: COMPARATOR
Intervention: Thermal Balloon Endometrial Ablation
Number of subjects: 320
Study: 17530950

Group type: EXPERIMENTAL
Intervention: Hypoxia group (H) at 2,320 m altitude
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoxia group (N) at sea level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comparison of AOD from EXP1 to EXP5
Number of subjects: 0
Study: 15470338

Group type: EXPERIMENTAL
Intervention: ACE inhibitor group (N = 19)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No ACE inhibitor group (N = 12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Smokers (ACE inhibitor group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nonsmokers (ACE inhibitor group)
Number of subjects: 31
Study: 11589265

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg BID
Number of subjects: 528

Group type: COMPARATOR
Intervention: Salmeterol 50 microg BID
Number of subjects: 528
Study: 9877003

Group type: COMPARATOR
Intervention: Tolrest (50 mg)
Number of subjects: 24
Study: 7961548

Group type: EXPERIMENTAL
Intervention: Antidepressant selection based on medical illness and therapeutic regimen
Number of subjects: 0